Skip to main content
Fig. 3 | Genome Medicine

Fig. 3

From: Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

Fig. 3

Exome sequencing data of SR PDX models. a Non-silent variant load and the thereof derived total number of driver or predicted driver mutations for CET-sensitive and primary resistant models. *, tumor with low sequencing coverage; MMR+, tumors with functional mismatch repair (MMR) system; MMR−, tumors with inactivating mutations in the MMR genes. b Cancer gene mutations identified in the 10 PDX models. Acquired mutations in the SR models are indicated by an asterisk. K, untreated control tumor; C, CET SR tumor

Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us